Cargando…

Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice

A fracture is a severe trauma that causes dramatic pain. Appropriate fracture pain management not only improves the patient’s subjective perception, but also increases compliance with rehabilitation training. However, current analgesics for fracture pain are unsatisfactory because of their negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jun, Xiao, Sheng, Xie, Juan, Fu, Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899823/
https://www.ncbi.nlm.nih.gov/pubmed/36755956
http://dx.doi.org/10.3389/fphar.2023.1046514
_version_ 1784882715760263168
author Peng, Jun
Xiao, Sheng
Xie, Juan
Fu, Wan
author_facet Peng, Jun
Xiao, Sheng
Xie, Juan
Fu, Wan
author_sort Peng, Jun
collection PubMed
description A fracture is a severe trauma that causes dramatic pain. Appropriate fracture pain management not only improves the patient’s subjective perception, but also increases compliance with rehabilitation training. However, current analgesics for fracture pain are unsatisfactory because of their negative effects on fracture healing or addiction problems. Bulleyaconitine A (BLA), a non-addictive analgesic medicine, is used for the treatment of chronic pain of musculoskeletal disorders in clinical practice, whereas the effects of BLA on fracture pain is undefined. To evaluate the analgesic effects of BLA on fracture, we generated tibial fracture mice here. It is found that oral administration of BLA to mice alleviates fracture-induced mechanical and thermal hyperalgesia. Interestingly, BLA significantly increases locomotor activity levels and reduces anxiety-like behaviors in fractured mice, as determined by open-field test. Notably, BLA treatment promotes bone mineralization and therefore fracture healing in mice, which may be attributed to the increase in mechanical stimulation caused by exercise. Our study suggests that BLA can be used as a promising analgesic agent for the treatment of fracture pain.
format Online
Article
Text
id pubmed-9899823
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98998232023-02-07 Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice Peng, Jun Xiao, Sheng Xie, Juan Fu, Wan Front Pharmacol Pharmacology A fracture is a severe trauma that causes dramatic pain. Appropriate fracture pain management not only improves the patient’s subjective perception, but also increases compliance with rehabilitation training. However, current analgesics for fracture pain are unsatisfactory because of their negative effects on fracture healing or addiction problems. Bulleyaconitine A (BLA), a non-addictive analgesic medicine, is used for the treatment of chronic pain of musculoskeletal disorders in clinical practice, whereas the effects of BLA on fracture pain is undefined. To evaluate the analgesic effects of BLA on fracture, we generated tibial fracture mice here. It is found that oral administration of BLA to mice alleviates fracture-induced mechanical and thermal hyperalgesia. Interestingly, BLA significantly increases locomotor activity levels and reduces anxiety-like behaviors in fractured mice, as determined by open-field test. Notably, BLA treatment promotes bone mineralization and therefore fracture healing in mice, which may be attributed to the increase in mechanical stimulation caused by exercise. Our study suggests that BLA can be used as a promising analgesic agent for the treatment of fracture pain. Frontiers Media S.A. 2023-01-23 /pmc/articles/PMC9899823/ /pubmed/36755956 http://dx.doi.org/10.3389/fphar.2023.1046514 Text en Copyright © 2023 Peng, Xiao, Xie and Fu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Peng, Jun
Xiao, Sheng
Xie, Juan
Fu, Wan
Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice
title Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice
title_full Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice
title_fullStr Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice
title_full_unstemmed Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice
title_short Bulleyaconitine A reduces fracture-induced pain and promotes fracture healing in mice
title_sort bulleyaconitine a reduces fracture-induced pain and promotes fracture healing in mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899823/
https://www.ncbi.nlm.nih.gov/pubmed/36755956
http://dx.doi.org/10.3389/fphar.2023.1046514
work_keys_str_mv AT pengjun bulleyaconitineareducesfractureinducedpainandpromotesfracturehealinginmice
AT xiaosheng bulleyaconitineareducesfractureinducedpainandpromotesfracturehealinginmice
AT xiejuan bulleyaconitineareducesfractureinducedpainandpromotesfracturehealinginmice
AT fuwan bulleyaconitineareducesfractureinducedpainandpromotesfracturehealinginmice